Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis

Sponsor
Janssen Research & Development, LLC
Study ID
NCT04948398
Status
No Longer Available

Conditions

  • Adenomatous Polyposis Coli

Eligibility Criteria

Sex
All
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Guselkumab — DRUG
    Guselkumab 100 milligrams (mg) will be administered subcutaneously once every 8 weeks.

Study Details

The purpose of this post-trial access (PTA) program is to provide guselkumab to participants with Familial Adenomatous Polyposis (FAP) who are experiencing clinical benefit after completing 48 weeks of treatment in Study CNTO1959COR1001.

Key Dates

Status verified
Jan 2025